Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced that it will release its financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, before the market opens. The company will also host a webcast at 8:30 a.m. Eastern Time on the same day.
During the webcast, Lifecore's senior management team will discuss the quarterly financial results and provide an update on recent corporate developments. Investors and interested parties can access the live webcast or archived version through the Investor Events & Presentations page on Lifecore's website at https://ir.lifecore.com/events-presentations.
Lifecore Biomedical (NASDAQ: LFCR), un'organizzazione completamente integrata per lo sviluppo e la produzione su contratto (CDMO), ha annunciato che rilascerà i suoi risultati finanziari per il primo trimestre dell'anno fiscale 2025 venerdì 4 ottobre 2024, prima dell'apertura del mercato. L'azienda ospiterà anche un webcast alle 8:30 ora orientale nello stesso giorno.
Durante il webcast, il team di alta dirigenza di Lifecore discorrerà sui risultati finanziari trimestrali e fornirà un aggiornamento sugli sviluppi aziendali recenti. Gli investitori e le parti interessate possono accedere al webcast dal vivo o alla versione registrata attraverso la pagina Eventi e Presentazioni per Investitori sul sito web di Lifecore all'indirizzo https://ir.lifecore.com/events-presentations.
Lifecore Biomedical (NASDAQ: LFCR), una organización completamente integrada de desarrollo y fabricación por contrato (CDMO), ha anunciado que publicará sus resultados financieros para el primer trimestre del año fiscal 2025 el viernes 4 de octubre de 2024, antes de la apertura del mercado. La compañía también llevará a cabo un webcast a las 8:30 a.m. hora del este el mismo día.
Durante el webcast, el equipo de alta dirección de Lifecore discutirá los resultados financieros trimestrales y proporcionará una actualización sobre los desarrollos corporativos recientes. Los inversionistas y partes interesadas pueden acceder al webcast en vivo o a la versión archivada a través de la página de Eventos y Presentaciones para Inversionistas en el sitio web de Lifecore en https://ir.lifecore.com/events-presentations.
Lifecore Biomedical (NASDAQ: LFCR)는 완전 통합된 계약 개발 및 제조 조직 (CDMO)으로, 2025 회계 연도 1분기 재무 결과를 2024년 10월 4일 금요일, 시장 개장 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 8:30 AM에 웹캐스트를 진행할 예정입니다.
웹캐스트 동안 Lifecore의 고위 경영진 팀은 분기 재무 결과에 대해 논의하고 최근 기업 개발에 대한 업데이트를 제공할 것입니다. 투자자 및 관심 있는 당사자는 Lifecore 웹사이트의 투자자 이벤트 및 프레젠테이션 페이지를 통해 https://ir.lifecore.com/events-presentations에서 라이브 웹캐스트 또는 보관된 버전에 접근할 수 있습니다.
Lifecore Biomedical (NASDAQ: LFCR), une organisation de développement et de fabrication sous contrat entièrement intégrée (CDMO), a annoncé qu'elle publiera ses résultats financiers pour le premier trimestre de l'exercice 2025 le vendredi 4 octobre 2024, avant l'ouverture des marchés. La société organisera également un webcast à 8h30, heure de l'Est le même jour.
Lors du webcast, l'équipe de direction de Lifecore discutera des résultats financiers trimestriels et fournira une mise à jour sur les développements récents de l'entreprise. Les investisseurs et les parties intéressées peuvent accéder au webcast en direct ou à la version enregistrée via la page Événements et Présentations pour Investisseurs sur le site Web de Lifecore à l'adresse https://ir.lifecore.com/events-presentations.
Lifecore Biomedical (NASDAQ: LFCR), ein vollständig integriertes Auftragsentwicklungs- und Herstellungsunternehmen (CDMO), hat angekündigt, dass es seine Finanzergebnisse für das erste Quartal des Geschäftsjahres 2025 am Freitag, den 4. Oktober 2024, vor der Markteröffnung veröffentlichen wird. Das Unternehmen wird am selben Tag auch ein Webcast um 8:30 Uhr Eastern Time veranstalten.
Während des Webcasts wird das Führungsteam von Lifecore die quartalsmäßigen Finanzergebnisse erörtern und ein Update zu den jüngsten Unternehmensentwicklungen geben. Investoren und Interessierte können auf das Live-Webcast oder die aufgezeichnete Version über die Seite für Investorenveranstaltungen und Präsentationen auf der Website von Lifecore unter https://ir.lifecore.com/events-presentations zugreifen.
- None.
- None.
CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore’s senior management team will discuss financial results for the first quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
FAQ
When will Lifecore Biomedical (LFCR) report its Q1 FY2025 financial results?
What time is Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast scheduled for?
Where can I access Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast?
What will be discussed during Lifecore Biomedical's (LFCR) Q1 FY2025 earnings call?
